Developing Drugs with Genetic Chemistry
Founded in 2004, Evolva has three main attributes:
- A unique technology platform that creates small molecule drugs from genetics – with $58 million of 3rd party funding to Evolva and our partners for discovery programs that utilize the platform.
- An attractive pipeline of potential pharmaceutical products deriving from this approach - two of which (cardiovascular, anti-fungal) are expected to enter Phase I in late 2008.
- An experienced team, following an aggressive, pragmatic, cost-effective and international business model, with operations in Switzerland, India, Denmark and the USA.
Over the next three years we aim to further develop our compound pipeline and technology base to a level of maturity that enables us to seek a public listing of our shares.
Evolva News
19th May, 2008
Evolva Subsidiary Signs $22.8 Million Antibacterial Contract with US Army Research Office, Builds Out US Operations
1st September, 2007